The United States Cancer Monoclonal Antibodies Market is supported by substantial healthcare spending, a high burden of various cancer types, and rapid adoption of innovative biologic therapies. Growing availability of approved monoclonal antibody treatments, expanding clinical research activities. The Cancer Monoclonal Antibodies Market was valued at US$ 167,627.55 million in 2024 and is...